

# Andrew Owen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7094597/publications.pdf>

Version: 2024-02-01

265  
papers

8,982  
citations

57758

44  
h-index

69250

77  
g-index

322  
all docs

322  
docs citations

322  
times ranked

11844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 421-423.	2.4	5
2	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	5.8	4
3	An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 585-594.	4.7	14
4	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106542.	2.5	7
5	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. <i>EBioMedicine</i> , 2022, 76, 103856.	6.1	38
6	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. <i>Viruses</i> , 2022, 14, 374.	3.3	12
7	Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. <i>Viruses</i> , 2022, 14, 1020.	3.3	58
8	Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. <i>Journal of Materials Chemistry B</i> , 2022, 10, 4395-4404.	5.8	3
9	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 64-68.	4.7	21
10	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2078-2088.	2.4	46
11	Long-acting drugs and formulations for the treatment and prevention of HIV infection. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106220.	2.5	63
12	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. <i>ACS Infectious Diseases</i> , 2021, 7, 1317-1331.	3.8	37
13	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 3.	1.6	5
14	A living WHO guideline on drugs to prevent covid-19. <i>BMJ</i> , The, 2021, 372, n526.	6.0	73
15	<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1874-1885.	3.0	65
16	Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5-triphosphate exposure to support posology for SARS-CoV-2. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2121-2128.	3.0	20
17	Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2230-2233.	3.0	17
18	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. <i>Aids</i> , 2021, 35, 1919-1927.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113848.	13.7	6
20	InÂvitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. <i>HIV Medicine</i> , 2021, 22, 898-906.	2.2	1
21	AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. <i>Trials</i> , 2021, 22, 487.	1.6	14
22	Singleâ€dose immunisation with a multimerised SARSâ€CoVâ€2 receptor binding domain (RBD) induces an enhanced and protective response in mice. <i>FEBS Letters</i> , 2021, 595, 2323-2340.	2.8	24
23	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. <i>Nature Communications</i> , 2021, 12, 5469.	12.8	102
24	Redispersible nanosuspensions as a plausible oral delivery system for curcumin. <i>Food Hydrocolloids</i> , 2021, 121, 107005.	10.7	17
25	Scalable nanoprecipitation of niclosamide and<i>in vivo</i> demonstration of long-acting delivery after intramuscular injection. <i>Nanoscale</i> , 2021, 13, 6410-6416.	5.6	11
26	Impact of long-acting therapies on the global HIV epidemic. <i>Aids</i> , 2021, 35, S137-S143.	2.2	16
27	<i>CYP2B6</i>*6 Genotype Specific Differences in Artemetherâ€Lumefantrine Disposition in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 351-360.	2.0	3
28	Critical considerations for targeting colorectal liver metastases with nanotechnology. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1588.	6.1	14
29	Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 640-647.	3.0	15
30	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
31	Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multi-layered nanocapsules for oral drug delivery. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118866.	5.2	45
32	Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. <i>International Journal of Pharmaceutics</i> , 2020, 588, 119794.	5.2	22
33	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 96-106.	1.5	1
34	Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1289-1295.	2.4	5
35	Safety perspectives on presently considered drugs for the treatment of COVIDâ€19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	5.4	17
36	In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5610.	4.1	7

#	ARTICLE	IF	CITATIONS
37	A living WHO guideline on drugs for covid-19. <i>BMJ, The</i> , 2020, 370, m3379.	6.0	664
38	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
39	Prioritization of Anti- <i>SARS-CoV-2</i> Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 775-790.	4.7	118
40	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
41	Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free anticoagulant activity. <i>Nanomedicine</i> , 2020, 15, 1361-1373.	3.3	0
42	Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. <i>Journal of Virus Eradication</i> , 2020, 6, 52-60.	0.5	38
43	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1259-1266.	3.0	6
44	Pharmacokinetics of HIV therapies in pregnant patients: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 449-461.	3.3	2
45	Designing single trigger/dual-response release and degradation into amine-functional hyperbranched-polydendron nanoprecipitates. <i>Nanoscale Advances</i> , 2020, 2, 5468-5477.	4.6	3
46	<i>CYP2B6</i> -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and <i>CYP2B6</i> -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
47	Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 30-36.	4.3	17
48	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 68, 446-452.	5.8	21
49	Meta-analysis of the effect of <i>CYP2B6</i> , <i>CYP2A6</i> , <i>UGT2B7</i> and <i>CAR</i> polymorphisms on efavirenz plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3281-3290.	3.0	15
50	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3003-3010.	3.0	13
51	Long-Acting Injectable Statins-“Is It Time for a Paradigm Shift?”. <i>Molecules</i> , 2019, 24, 2685.	3.8	7
52	Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 144, 101-109.	4.3	35
53	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 140, 105068.	4.0	17
54	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16

#	ARTICLE	IF	CITATIONS
55	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1670-1678.	3.0	42
56	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz035.	0.9	5
57	Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. <i>Nature Communications</i> , 2019, 10, 1413.	12.8	34
58	Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. <i>Nanoscale Advances</i> , 2019, 1, 4301-4307.	4.6	5
59	Pharmacogenetics of artemetherâ€¦lumefantrine influence on nevirapine disposition: Clinically significant drugâ€¦drug interaction?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 540-550.	2.4	6
60	Predicting Drugâ€¦Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. <i>Journal of Infectious Diseases</i> , 2019, 219, 1735-1742.	4.0	40
61	Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 149-156.	3.0	8
62	Towards a Maraviroc long-acting injectable nanoformulation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 92-98.	4.3	20
63	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. <i>Clinical Infectious Diseases</i> , 2018, 67, 785-790.	5.8	25
64	Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance<i>in vitro</i>. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 233-242.	2.0	8
65	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	17
66	Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 179-187.	2.2	11
67	Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems. <i>RSC Advances</i> , 2018, 8, 12984-12991.	3.6	32
68	Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. <i>Nature Communications</i> , 2018, 9, 315.	12.8	68
69	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drugâ€¦drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1004-1012.	3.0	15
70	Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 165-172.	3.0	8
71	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African motherâ€¦infant pairs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1013-1019.	3.0	30
72	In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2018, 57, 255-266.	3.5	26

#	ARTICLE	IF	CITATIONS
73	The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 223-236.	3.0	37
74	Advances in nanomedicine drug delivery applications for HIV therapy. <i>Future Science OA</i> , 2018, 4, FSO230.	1.9	15
75	The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV. <i>Nanomedicine</i> , 2018, 13, 1963-1965.	3.3	2
76	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. <i>Molecular Pharmaceutics</i> , 2018, 15, 4835-4842.	4.6	42
77	The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. <i>Advanced Drug Delivery Reviews</i> , 2018, 131, 116-121.	13.7	7
78	Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. <i>Journal of Nanobiotechnology</i> , 2018, 16, 22.	9.1	18
79	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	9
80	Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-11-30.	0.0	0
81	Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. <i>FASEB Journal</i> , 2018, 32, 828.3.	0.5	0
82	Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw485.	3.0	12
83	Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. <i>Nanotoxicology</i> , 2017, 11, 147-149.	3.0	29
84	Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	10
85	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 529-536.	4.7	28
86	A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. <i>European Journal of Nanomedicine</i> , 2017, 9, .	0.6	6
87	Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	28
88	Integrated pharmacokinetic modelling for accelerated nanomedicine translation. <i>European Journal of Nanomedicine</i> , 2017, 9, 1-3.	0.6	1
89	Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00359.	2.4	12
90	Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. <i>Nanomedicine</i> , 2017, 12, 2043-2054.	3.3	5

#	ARTICLE	IF	CITATIONS
91	Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	7
92	Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity. <i>Journal of Interdisciplinary Nanomedicine</i> , 2017, 2, 146-156.	3.6	12
93	In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. <i>Journal of Interdisciplinary Nanomedicine</i> , 2017, 2, 157-169.	3.6	0
94	Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico , In Vitro , and In Vivo Investigation. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
95	Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 200-204.	3.0	8
96	Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 190-199.	3.0	10
97	Towards a computational prediction of nanoparticle pharmacokinetics and distribution. <i>Journal of in Silico &amp; in Vitro Pharmacology</i> , 2016, 02, .	0.2	4
98	Pregnancy affects nevirapine pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 381-389.	1.5	10
99	<i>Occupational Safety and Health</i> . , 2016, , 331-354.		0
100	Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. <i>Nanomedicine</i> , 2016, 11, 1447-1464.	3.3	28
101	Validation of Computational Approaches for Antiretroviral Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3838-3839.	3.2	2
102	Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. <i>Bioanalysis</i> , 2016, 8, 2125-2134.	1.5	2
103	Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma. <i>HIV Clinical Trials</i> , 2016, 17, 197-203.	2.0	2
104	Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. <i>Pharmacogenomics</i> , 2016, 17, 891-906.	1.3	5
105	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 185-198.	2.4	28
106	Interdisciplinary nanomedicine publications through interdisciplinary peer-review. <i>Journal of Interdisciplinary Nanomedicine</i> , 2016, 1, 4-8.	3.6	1
107	Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. <i>Journal of Interdisciplinary Nanomedicine</i> , 2016, 1, 110-123.	3.6	17
108	Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. <i>Nature Communications</i> , 2016, 7, 13184.	12.8	44

#	ARTICLE	IF	CITATIONS
109	Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. <i>Toxicology Letters</i> , 2016, 246, 17-27.	0.8	16
110	Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 144-156.	13.7	113
111	Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. <i>Frontiers in Nanobiomedical Research</i> , 2016, , 205-239.	0.1	0
112	Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields. <i>Nanoscale</i> , 2016, 8, 7224-7231.	5.6	9
113	Emerging nanomedicine applications and manufacturing: progress and challenges. <i>Nanomedicine</i> , 2016, 11, 577-580.	3.3	3
114	Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600Åmg in Treatment-NaÅve HIV-Infected Patients at 96ÅWeeks: Results of the ENCORE1 Study. <i>Clinical Pharmacokinetics</i> , 2016, 55, 861-873.	3.5	51
115	Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1031-1036.	3.0	29
116	Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 617-620.	3.2	12
117	Chapter 12. The Challenge of Regulating Nanomedicine: Key Issues. <i>RSC Drug Discovery Series</i> , 2016, , 290-314.	0.3	9
118	Pharmacogenetics of pregnancyâ€induced changes in efavirenz pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 298-306.	4.7	39
119	Towards depersonalized abacavir therapy. <i>Aids</i> , 2015, 29, 2385-2395.	2.2	15
120	The Application of Nanotechnology toÂDrug Delivery in Medicine. , 2015, , 173-223.		12
121	Pharmacokinetic and Pharmacodynamic Comparison of Onceâ€Daily Efavirenz (400 mg vs. 600 mg) in Treatmentâ€NaÅve HIVâ€Infected Patients: Results of the ENCORE1 Study. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 406-416.	4.7	72
122	Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. <i>Clinical Pharmacokinetics</i> , 2015, 54, 107-116.	3.5	2
123	Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 1026-1032.	5.8	27
124	Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and Aâ€B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media. <i>Macromolecules</i> , 2015, 48, 1883-1893.	4.8	8
125	Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research. <i>Journal of Infectious Diseases</i> , 2015, 211, S115-S125.	4.0	27
126	Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. <i>Frontiers in Pharmacology</i> , 2015, 6, 78.	3.5	19



#	ARTICLE	IF	CITATIONS
127	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2816-2822.	3.0	21
128	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 453-463.	5.8	32
129	No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e56-e59.	2.1	10
130	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 555-561.	3.0	35
131	Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. <i>Chemical Science</i> , 2015, 6, 326-334.	7.4	31
132	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3074-3079.	3.0	11
133	Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons. <i>Soft Matter</i> , 2015, 11, 7005-7015.	2.7	15
134	Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. <i>Pharmacogenomics</i> , 2015, 16, 919-928.	1.3	14
135	Considerations for clinically-relevant nanomedicine therapies for chronic diseases. <i>Nanomedicine</i> , 2015, 10, 3103-3107.	3.3	4
136	Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. <i>Journal of Controlled Release</i> , 2015, 219, 669-680.	9.9	39
137	Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. <i>Therapeutic Delivery</i> , 2015, 6, 469-490.	2.2	31
138	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. <i>Molecular Pharmaceutics</i> , 2015, 12, 3556-3568.	4.6	15
139	Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. <i>Clinical Pharmacokinetics</i> , 2015, 54, 639-650.	3.5	79
140	Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. <i>Nanomedicine</i> , 2015, 10, 1407-1421.	3.3	9
141	The role of drug transporters in the kidney: lessons from tenofovir. <i>Frontiers in Pharmacology</i> , 2014, 5, 248.	3.5	62
142	Special issue of <i>BJP</i> on <i>Nanomedicine</i> . <i>British Journal of Pharmacology</i> , 2014, 171, 3961-3962.	5.4	6
143	CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 734-738.	2.0	10
144	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 459-463.	1.5	21

#	ARTICLE	IF	CITATIONS
145	A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3275-3281.	3.0	3
146	Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. <i>Advanced Healthcare Materials</i> , 2014, 3, 400-411.	7.6	73
147	Is methanol really a bad solvent for poly(n-butyl methacrylate)? Low dispersity and high molecular weight polymers of n-butyl methacrylate synthesised via ATRP in anhydrous methanol. <i>Polymer Chemistry</i> , 2014, 5, 3608-3616.	3.9	12
148	New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. <i>Drugs</i> , 2014, 74, 7-13.	10.9	35
149	Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. <i>Chemical Science</i> , 2014, 5, 1844-1853.	7.4	42
150	Enabling the genomic revolution in Africa. <i>Science</i> , 2014, 344, 1346-1348.	12.6	361
151	Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 491-499.	3.0	53
152	Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a “mixed matrix”™. <i>Nanomedicine</i> , 2014, 9, 2467-2479.	3.3	16
153	Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs. , 2014, , 339-360.		4
154	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , 2013, 1, 4.	3.3	26
155	Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. <i>Clinical Pharmacokinetics</i> , 2013, 52, 583-592.	3.5	47
156	High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i> . <i>Journal of Materials Chemistry B</i> , 2013, 1, 4455.	5.8	15
157	Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6366-6369.	3.2	112
158	Transport of gabapentin by LAT1 (SLC7A5). <i>Biochemical Pharmacology</i> , 2013, 85, 1672-1683.	4.4	120
159	Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching. <i>Green Chemistry</i> , 2013, 15, 1590.	9.0	3
160	Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. <i>Clinical Pharmacokinetics</i> , 2013, 52, 543-553.	3.5	32
161	Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients. <i>Molecular Pharmaceutics</i> , 2013, 10, 2739-2748.	4.6	36
162	Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. <i>Xenobiotica</i> , 2013, 43, 920-931.	1.1	28

#	ARTICLE	IF	CITATIONS
163	Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 78-83.	2.0	35
164	Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2545-2549.	3.0	5
165	Predicting intestinal absorption of raltegravir using a population-based ADME simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1627-1634.	3.0	26
166	Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5612-5618.	3.2	26
167	Research Spotlight: Nanomedicines for HIV therapy. <i>Therapeutic Delivery</i> , 2013, 4, 153-156.	2.2	23
168	RXR $\beta$ gene variants are associated with HIV lipodystrophy. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 438-441.	1.5	4
169	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. <i>Future Virology</i> , 2013, 8, 871-890.	1.8	10
170	Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 60-66.	2.1	12
171	ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 314-323.	1.5	26
172	Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e69266.	2.5	19
173	A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. <i>PLoS ONE</i> , 2013, 8, e64854.	2.5	25
174	Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 675-680.	3.0	8
175	Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 671-674.	3.0	22
176	Inpatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235.	2.0	30
177	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2959-2966.	3.2	39
178	Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 724-732.	5.8	144
179	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 10-19.	1.5	38
180	Facile synthesis of complex multi-component organic and organo-magnetic inorganic nanocomposite particles. <i>Journal of Materials Chemistry</i> , 2012, 22, 24744.	6.7	20

#	ARTICLE	IF	CITATIONS
181	Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3020-3026.	3.2	52
182	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. <i>Pharmacogenomics</i> , 2012, 13, 1501-1522.	1.3	23
183	Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i> – <i>In Vivo</i> Extrapolation Model. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 494-502.	4.7	48
184	Regulation of CYP3A4 and CYP3A5 expression and modulation of $\alpha$ -intraconazole metabolism of androgens in prostate cells by liganded vitamin D receptor. <i>Molecular and Cellular Endocrinology</i> , 2012, 364, 54-64.	3.2	23
185	Estimation of the Effect of <i>SLCO1B1</i> Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults. <i>Antiviral Therapy</i> , 2012, 17, 861-868.	1.0	26
186	Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. <i>Advanced Functional Materials</i> , 2012, 22, 2469-2478.	14.9	56
187	Lamotrigine is a substrate for OCT1 in brain endothelial cells. <i>Biochemical Pharmacology</i> , 2012, 83, 805-814.	4.4	73
188	Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2092-2098.	3.0	93
189	Current Progress in the Pharmacogenetics of Infectious Disease Therapy. , 2011, , 555-578.		3
190	The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 341-352.	3.3	11
191	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 344-349.	2.1	16
192	IFN- $\gamma$ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 442-445.	2.1	3
193	Adipogenic gene variants in patients with HIV-associated lipodystrophy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 76-83.	1.5	7
194	Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. <i>Malaria Journal</i> , 2011, 10, 42.	2.3	28
195	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. <i>Molecular Cancer</i> , 2011, 10, 37.	19.2	200
196	Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1332-1339.	3.0	46
197	Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. <i>Journal of Infectious Diseases</i> , 2011, 204, 145-153.	4.0	102
198	The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4122-4127.	3.2	130

#	ARTICLE	IF	CITATIONS
199	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 688-688.	3.0	0
200	Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 879-887.	3.2	58
201	Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. <i>PLoS ONE</i> , 2011, 6, e16800.	2.5	39
202	HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 112-120.	1.5	160
203	The accumulation and metabolism of zidovudine in 3T3 adipocytes. <i>British Journal of Pharmacology</i> , 2010, 159, 484-493.	5.4	8
204	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 759-765.	1.5	38
205	Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1889-1893.	3.0	40
206	Population Pharmacokinetic Modeling of the Association between 63396C>T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.	3.2	66
207	Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 51-65.	6.1	12
208	Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1002-1007.	3.0	41
209	Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. <i>Clinical Infectious Diseases</i> , 2009, 48, e108-e116.	5.8	221
210	<i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1722-1723.	3.2	1
211	Intracellular "boosting" of darunavir using known transport inhibitors in primary PBMC. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 375-380.	2.4	15
212	The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 204-211.	4.7	14
213	The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. <i>British Journal of Pharmacology</i> , 2009, 156, 497-508.	5.4	73
214	Cytochrome P450 2B6 516G>T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. <i>HIV Medicine</i> , 2009, 10, 310-317.	2.2	71
215	Nanomedicine: Not a case of "One size fits all". <i>Nano Today</i> , 2009, 4, 382-384.	11.9	18
216	The impact of pharmacogenetics on HIV therapy. <i>International Journal of STD and AIDS</i> , 2009, 20, 145-151.	1.1	24

#	ARTICLE	IF	CITATIONS
217	Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. <i>British Journal of Pharmacology</i> , 2008, 155, 875-883.	5.4	40
218	Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>British Journal of Pharmacology</i> , 2008, 153, 805-819.	5.4	94
219	Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. <i>Journal of Immunological Methods</i> , 2008, 339, 270-274.	1.4	9
220	<i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3883-3888.	3.2	11
221	Drug-Regulated Expression of <i>Plasmodium falciparum</i> P-Glycoprotein Homologue 1: a Putative Role for Nuclear Receptors. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1438-1445.	3.2	7
222	Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial bc1 Complex. <i>Molecular Pharmacology</i> , 2008, 73, 1347-1355.	2.3	85
223	Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 914-918.	3.0	169
224	Association of a Single Nucleotide Polymorphism in the Pregnane X Receptor ( <i>PXR</i> 63396C>T) with Reduced Concentrations of Unboosted Atazanavir. <i>Clinical Infectious Diseases</i> , 2008, 47, 1222-1225.	5.8	77
225	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1188-1190.	3.0	3
226	Pharmacogenetics of antiretroviral agents. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 288-295.	3.8	10
227	Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 881-884.	3.0	7
228	Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 685-689.	3.0	19
229	Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 987-993.	3.0	99
230	Tacrine-induced liver damage: an analysis of 19 candidate genes. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1091-1100.	1.5	37
231	Detection and biochemical characterisation of a novel polymorphism in the human GSTP1 gene. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007, 1770, 1240-1247.	2.4	15
232	Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. <i>Tuberculosis</i> , 2007, 87, 248-255.	1.9	119
233	Effect of Transporter Modulation on the Emergence of Nelfinavir Resistance <i>In Vitro</i> . <i>Antiviral Therapy</i> , 2007, 12, 831-834.	1.0	6
234	Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals. <i>Clinical Pharmacokinetics</i> , 2006, 45, 213-214.	3.5	1

#	ARTICLE	IF	CITATIONS
235	Pharmacogenetics of HIV therapy. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 693-703.	1.5	43
236	Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 439-450.	1.5	62
237	Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 237-242.	2.4	41
238	The impact of host pharmacogenetics on antiretroviral drug disposition. <i>Current Infectious Disease Reports</i> , 2006, 8, 401-408.	3.0	6
239	Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. <i>American Journal of Physiology - Cell Physiology</i> , 2006, 290, C104-C115.	4.6	27
240	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1390-1393.	0.9	20
241	Host determinants of antiretroviral drug activity. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 543-549.	3.1	13
242	Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. <i>Aids</i> , 2005, 19, 2097-2102.	2.2	84
243	The implications of P-glycoprotein in HIV: friend or foe?. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 283-296.	1.9	41
244	Relationship between the C <sup>3435</sup> T and G <sup>2677</sup> T(A) polymorphisms in the <i>ABC B1</i> gene and P-glycoprotein expression in human liver. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 365-370.	2.4	69
245	In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1202-1209.	2.5	26
246	Mitochondria are sensors for HIV drugs. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 258-264.	8.7	33
247	Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4. <i>Journal of Virology</i> , 2004, 78, 12022-12029.	3.4	44
248	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. <i>Transplantation</i> , 2004, 77, 557-561.	1.0	20
249	Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. <i>Antiviral Therapy</i> , 2004, 9, 819-21.	1.0	26
250	Intracellular pharmacokinetics of antiretroviral agents. <i>Journal of HIV Therapy</i> , 2004, 9, 97-101.	0.6	17
251	Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna. <i>Antiviral Therapy</i> , 2004, 9, 819-821.	1.0	60
252	A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. <i>Journal of Immunological Methods</i> , 2003, 274, 129-137.	1.4	26

#	ARTICLE	IF	CITATIONS
253	The mechanisms that control intracellular penetration of the HIV protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 493-496.	3.0	37
254	Differential Expression of Human Immunodeficiency Virus Coreceptors, by CEM, CEMVBL, and CEM E1000Cells. <i>Journal of Infectious Diseases</i> , 2003, 187, 874-875.	4.0	8
255	The Effects of Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors on P-Glycoprotein Expression in Peripheral Blood Mononuclear Cells In Vitro. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 551-556.	2.1	89
256	Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKII(MRP1) and MDCKII(MRP2) cell lines. <i>Aids</i> , 2003, 17, 2276-2278.	2.2	7
257	Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines. <i>Aids</i> , 2003, 17, 2276-8.	2.2	4
258	LC determination of carbamazepine in murine brain. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2001, 26, 573-577.	2.8	16
259	Carbamazepine is not a substrate for P-glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 345-349.	2.4	123
260	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , 0, 6, 246.	1.8	1
261	Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. , 0, , 71-96.		1
262	Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. <i>AAS Open Research</i> , 0, 1, 16.	1.5	11
263	Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) â€” Protocol and data analysis plan for a cohort study. <i>Wellcome Open Research</i> , 0, 4, 34.	1.8	4
264	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , 0, 6, 246.	1.8	0
265	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , 0, 6, 246.	1.8	1